Table 1.
Response of ADP-stimulated contraction with cMyBPC and control antibodies
| Sample | Before | After | ns |
| N′ cMyBPC ab (2.2 μm) | N′ cMyBPC ab (2.2 μm) | ||
| IDCM | n = 4, n = 11 | ||
| ADP–Fact, kN/m2 | 8.4 ± 1.0 | 6.6 ± 0.9* | |
| ADP–Fpass, kN/m2 | 0.36 ± 0.1 | 0.33 ± 0.1 | |
| Nucleolar ab (2.2 μm) | Nucleolar ab (2.2 μm) | n = 3, n = 8 | |
| IDCM | |||
| ADP–Fact, kN/m2 | 9.3 ± 1.1 | 9.0 ± 1.0 | |
| ADP–Fpass, kN/m2 | 0.57 ± 0.1 | 0.50 ± 0.1 | |
| C′ cMyBPC ab (2.2 μm) | C′ cMyBPC ab (2.2 μm) | n = 3, n = 11 | |
| IDCM | |||
| ADP–Fact, kN/m2 | 11.7 ± 1.9 | 10.8 ± 2.0 | |
| ADP–Fpass, kN/m2 | 1.5 ± 0.3 | 1.2 ± 0.2* |
Paired-samples t test. P < 0.05 was considered significant; *vs. before antibodies. C′ cMyBPC or nucleolar antibody served as controls for unspecific binding. ab, antibody; ADP–Fact, ADP total tension (10 mM ADP); ADP–Fpass, ADP passive tension; cMyBPC, cardiac myosin-binding protein C; IDCM, idiopathic dilated cardiomyopathy; N, number of samples; n, number of cardiomyocytes; 2.2-μm sarcomere length.